A single fusion protein combining porcine interleukin-2, interferon-α and thymosin α1 showed antiviral activity against pseudorabies virus, according to a study published online October 8, 2026, in Veterinary Microbiology.

The work comes from a nine-author team led by Wenkai Zhang of Yangzhou University, with colleagues including Shaoyan Qi, Aijun Sun and Guoqing Zhuang. The group engineered the three immunomodulatory molecules into one tripartite construct and tested its activity against pseudorabies virus, the causative agent of Aujeszky's disease.

What did the researchers build?

The construct links three cytokine and peptide components into a single recombinant protein:

• Porcine interleukin-2, a T-cell growth factor that drives adaptive immune expansion
• Interferon-α, a frontline antiviral cytokine of the innate response
• Thymosin α1, a peptide with established immunomodulatory credentials

The rationale is straightforward. Each component acts on a different arm of antiviral immunity. Fusing them into one molecule aims to deliver coordinated stimulation in a single agent rather than three separate injections. The study title states the outcome plainly: the fusion protein confers antiviral activity against pseudorabies virus.

Why pseudorabies matters at the barn level

Pseudorabies virus remains a production-limiting pathogen in swine herds across regions where eradication is incomplete. Vaccination is the mainstay of control, but the virus persists in ways that keep immunization strategies under review.

For practitioners, a cytokine-based antiviral represents a different tool class from vaccines. Vaccines prevent infection through antigen-specific immunity. An immunomodulatory fusion protein works upstream, reshaping the host response to the virus itself. The two approaches are complementary in principle, not interchangeable.

The species scope here is swine. The study does not extend to companion animals, and readers should not extrapolate the findings beyond the porcine system tested.

What changes for practice now?

Nothing yet, and that is the honest answer. This is an early-stage proof of antiviral activity, published in a peer-reviewed microbiology journal, not a licensed product.

The construct carries no regulatory approval from any agency — not the USDA's Center for Veterinary Biologics, which oversees swine biologics in the United States, and not counterpart agencies elsewhere. Any path from this paper to a marketable product would require formulation development, target-animal safety studies, efficacy trials under field conditions, and a full regulatory dossier.

That path typically runs several years and carries high attrition. Practitioners should file this under promising rather than actionable.

Why cytokine fusion matters as a design strategy

The tripartite design is the more interesting signal for the field. Combination cytokine therapy has faced practical obstacles: separate molecules, separate stability profiles, separate dosing. A single-chain fusion protein solves the delivery problem at the molecular level.

If the approach generalizes, it could apply to other viral diseases of livestock where host-directed therapy has lagged behind vaccination. That is a hypothesis for future work, not a finding of this paper.

The study contributes a validated construct and a demonstrated antiviral effect against pseudorabies virus. Whether the fusion protein reaches a commercial pipeline will depend on data the authors have yet to generate.

The takeaway

A three-in-one porcine cytokine construct has shown antiviral activity against pseudorabies virus in a study published October 8, 2026. It is a research-stage finding with no current clinical use, and herds will keep relying on existing vaccination programs while this work matures.